Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer

Advances in Therapy

Volumn 30, Issue 12, 2013, Pages 1041-1066

  Malik, Zafar ^a   Payne, Heather ^b   Ansari, Jawaher ^c   Chowdhury, Simon ^d   Butt, Mohammad ^e   Birtle, Alison ^f   Sundar, Santhanam ^g   Eswar, Chinnamani Vee ^a   Hughes, Simon ^d   Bahl, Amit ^h  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e CASTLE HILL HOSPITAL   (United Kingdom)

^f LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Abiraterone acetate; Cabazitaxel; Enzalutamide; Metastatic castration resistant prostate cancer; Oncology; Radium 223; Sipuleucel T; Treatment sequencing

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; BICALUTAMIDE; CABAZITAXEL; CISPLATIN; CYTOTOXIC AGENT; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; IPILIMUMAB; JNJ 212082; LEUPRORELIN; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISOLONE; PREDNISONE; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ABDOMINAL PAIN; ALTERNATIVE MEDICINE; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BLOOD BRAIN BARRIER; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PAIN; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CELL LEVEL; CHILL; CLINICAL FEATURE; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; DISEASE RESISTANCE; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; EDEMA; ELECTRON THERAPY; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; GENETIC DIFFERENCE; GOLD STANDARD; HEADACHE; HEART DISEASE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; JAW OSTEONECROSIS; LEUKAPHERESIS; LEUKOPENIA; LICENSING; LIVER DYSFUNCTION; LOW DRUG DOSE; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PATIENT DECISION MAKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REVIEW; SEIZURE; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNCONSCIOUSNESS; AGED; ALGORITHM; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; DRUG RESISTANCE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK ASSESSMENT; SURVIVAL; TOTAL QUALITY MANAGEMENT; UNITED KINGDOM;

AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHENYLTHIOHYDANTOIN; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY IMPROVEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84890547802     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0070-z     Document Type: Review

References (58)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389-96.
3. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Prostate Cancer (Version 4.2013). 2013. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed 12 Sept 2013.
4. Horwich A, Parker C, Bangma C, Kataja V. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v129-33.
5. Scott WW, Johnson DE, Schmidt JE, et al. Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. J Urol. 1975;114:909-11.
6. George DJ, Kantoff PW, Lin DW. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol. 2011;9:1-11.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
8. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-5.
9. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
10. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. 2013. http://www.uroweb.org/guidelines/online-guidelines/. Accessed 21 Oct 2013.
11. Caffo O, Sava T, Comploj E, et al. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. BJU Int. 2011;108:1825-32.
12. O'Neill AJ, Prencipe M, Dowling C, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011;10:126.
13. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999;17:1061-70.
14. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-16.
15. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723-30.
16. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol. 2003;138:1367-75.
17. Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47:1037-45.
18. Fumoleau P, Trigo J, Campone M, et al. Phase I and pharmacokinetics (PK) study of RPR116258A given as a weekly 1-hour infusion at day 1, day 8, day 15 and day 22 every 5 weeks in patients (PTS) with advanced solid tumors. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 29 October-2 November, 2001. Miami, FL, USA.
19. Diéras V, Lortholary A, Laurence V, et al. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Eur J Cancer. 2013;49:25-34.
20. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-54.
21. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7:497-506.
22. ® (cabazitaxel) Injection [Prescribing Information]: Bridgewater: Sanofi U.S. LLC; 2010. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/201023lbl.pdf. Accessed 12 Sept 2013.
23. Ozguroglu M, Oudard S, Sartor AO, et al. Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study. J Clin Oncol. 2011;29 Suppl 7:Abstract 144.
24. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-205.
25. ® (cabazitaxel) Injection [Summary of Product Characteristics]. Paris: Sanofi; 2013. http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/002018/human-med-001428.jsp&mid= WC0b01ac058001d124. Accessed 12 Sept 2013.
26. 2 with prednisone for the treatment of metastatic castration resistant prostate cancer (PROSELICA). 2013. http://www. clinicaltrials.gov/show/NCT01308580. Accessed 12 Sept 2013.
27. ClinicalTrials.gov [Web site]. Early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen. 2013. http://www.clinicaltrials.gov/show/ NCT01254279. Accessed 12 Sept 2013.
28. Malik Z, di Lorenzo G, Basaran M, et al. Cabazitaxel (cbz) + prednisone (P; CbzP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): interim results from compassionate-use programme (CUP) and early-access programme (EAP). Ann Oncol. 2012;23:Abstract 931P.
29. Bracarda S, di Lorenzo G, Gaspamo D, et al. Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2012;30 Suppl 5:Abstract 253.
30. Bahl A, Masson S, Malik Z, et al. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access programme (NCT01254279). European Association of Urology Congress, 24-28 February 2012. Paris, France. Abstract 129.
31. Heidenreich A, Scholz HJ, Rogenhofer S, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol. 2013;63:977-82.
32. de Bono JS, Oudard S, Ozguroglu M, et al. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2011;29 Suppl:Abstract 4526.
33. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009;15:3251-5.
34. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447-54.
35. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell. 2009;16:458-62.
36. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742-8.
37. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440-8.
38. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563-71.
39. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28:1496-501.
40. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489-95.
41. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
42. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-92.
43. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-48.
44. Zytiga (abiraterone acetate) Tablets for Oral Administration [Summary of Product Characteristics]. Beerse: Janssen-Cilag International NV; 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002321/human-med-001499.jsp&mid=WC0b01ac058001d124. Accessed 12 Sept 2013.
45. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-90.
46. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97.
47. ® (enzalutamide) Capsules for Oral Use [Prescribing Information]. Silver Spring: Astellas Pharma US, Inc; 2012. http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/203415lbl.pdf. Accessed 12 Sept 2013.
48. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-42.
49. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813-22.
50. Xgeva (denosumab) Injection, for Subcutaneous Use, [Prescribing Information]. Thousand Oaks: Amgen Inc.; 2010. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/125320s007lbl.pdf. Accessed 12 Sept 2013.
51. XGEVA 120 mg Solution for Injection [Summary of Product Characteristics]. Breda: Amgen Europe BV; 2011. http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/002173/human-med-001463.jsp. Accessed 12 Sept 2013.
52. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-23.
53. Xofigo (radium Ra 223 dichloride) Injection, for intravenous use, [Prescribing Information]. Wayne: Bayer HealthCare Pharmaceuticals Inc.; 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/203971lbl.pdf. Accessed 12 Sept 2013.
54. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. PT. 2011;36:197-202.
55. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
56. ® (sipuleucel-T) Suspension for intravenous infusion [Highlights of Prescribing Information]. Seattle: Dendreon Corporation; 2010. http://www.fda.gov/downloads/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf. Accessed 12 Sept 2013.
57. EMA. Provenge. 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/002513/smops/Positive/human-smop-000538.jsp&mid= WC0b01ac058001d127. Accessed 12 Sept 2013.
58. Mukherji D, Pezaro CJ, Bianchini D, Zivi A, de Bono JS. Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel. J Clin Oncol. 2012;30 Suppl 5:Abstract 17.